Since glycosylation processes are frequently altered in cancer (29–31), we recently engaged in an antibody development campaign to identify antibodies that would recognize tumor specific glycoepitopes on Podxl but not react with Podxl expressed by normal tissue (32). Here, PODXL is linked to cancer.